AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $3.66 per share a year ago.

Abbvie (NYSE:ABBV) raised its 2023 profit guidance after a strong quarterly earnings report driven by demand for newer drugs and better-than-expected Humira performance. During 3Q 2023 Abbvie (NYSE...

Shares of AbbVie Inc. NYSE: ABBV have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company's results but has done nothing...

AbbVie raises earnings guidance for fiscal 2023.

AbbVie on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong dema...

AbbVie Inc. ABBV, -0.04% on Friday reported third-quarter sales and profit that topped analyst expectations and raised its full-year earnings outlook, even as its blockbuster autoimmune drug Humira...

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AbbVie has good reasons for investors to take a close look at the stock, even though its best-selling drug recently lost patent exclusivity. Tandem Diabetes Care has plenty of room to increase sale...

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day.

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recently, investors searching for dividend stocks to buy have seen more opportunity. Some looking for income over a longer term horizon have flooded into the bond market.

With market uncertainty practically being the only form of certainty available, investors should consider dividend aristocrats. By definition, companies under this category belong in the S&P 500 in...

AbbVie's valuation is elevated, though it has no major catalysts coming up. It's also seeing sales of its biggest-earning medicine erode rapidly.

The US FDA has already approved two directly interchangeable biosimilars to ABBV's Humira, namely Boehringer Ingelheim's Cyltezo and PFE's ABRILADA. The impact on ABBV's sales may be great, since i...